{"name":"Orasis Pharmaceuticals Ltd.","slug":"orasis-pharmaceuticals-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CSF-1","genericName":"CSF-1","slug":"csf-1","indication":"Immune reconstitution and myeloid cell recovery in immunocompromised patients","status":"phase_3"},{"name":"CSF-1 Component #2","genericName":"CSF-1 Component #2","slug":"csf-1-component-2","indication":"Treatment of autoimmune diseases","status":"phase_2"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CSF-1 Component #1","genericName":"CSF-1 Component #1","slug":"csf-1-component-1","indication":"Treatment of age-related macular degeneration","status":"phase_2"}]}],"pipeline":[{"name":"CSF-1 Component #1","genericName":"CSF-1 Component #1","slug":"csf-1-component-1","phase":"phase_2","mechanism":"CSF-1 Component #1 is a protein that modulates the activity of the colony-stimulating factor 1 receptor.","indications":["Treatment of age-related macular degeneration"],"catalyst":""},{"name":"CSF-1","genericName":"CSF-1","slug":"csf-1","phase":"phase_3","mechanism":"CSF-1 is a recombinant human colony-stimulating factor 1 that promotes the growth and differentiation of myeloid progenitor cells.","indications":["Immune reconstitution and myeloid cell recovery in immunocompromised patients"],"catalyst":""},{"name":"CSF-1 Component #2","genericName":"CSF-1 Component #2","slug":"csf-1-component-2","phase":"phase_2","mechanism":"CSF-1 Component #2 is a protein that modulates immune cell function.","indications":["Treatment of autoimmune diseases"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQT2RUTUcybzZ1WThCY1doNmhxQmN5b195TTNDQTE2WHhZTEJGMWh0VkZZR0xYdEw3Vk5JX0Y1VlVMcTQtTmVuSnowdjNpRjdGN2podzEwRXRkdE02NG1XUHdDVFJROWhQZWlaZGRTeTlWZFZRaEs2SHEyeFZEUjFGMVpQS2Vna3JtQjRPV0xRaVRkdEw1ZWpieVlB?oc=5","date":"2026-03-12","type":"pipeline","source":"openPR.com","summary":"Presbyopia Pipeline Insight Expands as 10+ Pharma Companies - openPR.com","headline":"Presbyopia Pipeline Insight Expands as 10+ Pharma Companies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxONnJhS2I3anBDREZuaENXVENVVWVhTXhwWHdvUlFVUWxtQlpBaDdGekI0UV9IaDJQTk5maWhpa3JZWDdISmpVN1pwZjd5cDg5RFdDd1NlR2RBOHFuWHBLNExDSE1DcW1EUzdJX0c5eGtQVk5PMFAwcWFYeng1S2NEVmlfal9ldGNoVjI2QnVJQjJ6d2pmcUs0U2p0UWUtOWFGSE53akZOYS1oTndza1hvV1Rrb3pkRS1RdmFiVVJvaTQ4eUpkWi0wdEZ2MFM1TE1MM3dlRExBeTdpaW81WG9UWVB1LW9KWkg2aEN6TmZYRHFRWmdrMnVuekdyMHdCQTA5ZUhaNjhlOGRPWlRqVDZiUDN2UQ?oc=5","date":"2026-01-27","type":"pipeline","source":"PR Newswire","summary":"/C O R R E C T I O N -- Orasis Pharmaceuticals/ - PR Newswire","headline":"/C O R R E C T I O N -- Orasis Pharmaceuticals/","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQcExUbEVCaW84TUNRS00xbU9sTVpHb3VFZFBIcTN4MUo3T212cVlpMHVxY3MxN25Xam9UOFU1TVlDalRVSjY3WXF3M016NXJrOWVuaWNLc3lMTEdwMVl5cmw3Wk9JR1dqT3J1V19paks4bm50ZkxBejlqeHpYMndMN3hnaFMtcDFVdU5admhPYjVIejA?oc=5","date":"2025-11-13","type":"pipeline","source":"Yahoo Finance","summary":"ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL ROLLOUT - Yahoo Finance","headline":"ORASIS PHARMACEUTICALS EXPANDS ACCESS TO QLOSI™ WITH NEW STARTER PACKS FOR EYE CARE PROFESSIONALS, BOLSTERING COMMERICAL","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPVnh1V3FPcjQzdlh5MThHcWNpVUx3cjd3ZDFmWHBIRzJFaG5Fa3YxVFBrOG51Q1VIX05rRU1WSjdmV1N6cldLZldEZmhtMk50WjkxZXA4TGhjVlpJTWNrS2ozTnpyMkJCZ0xIU1JVaDFwNkJQOXJ3YkJLWlVKcEZVYTc2dHBoaTVEV2NzVFRkcHV3SXFhdVN0cnV4QTc3VHlvQS1GenUtU0prRzk2MVR1a1FVeHZ4Z3lWRXVjRV9jZklqTFM3anRzTEpickRVNXQ0NmhEX0JxRjV0cGlTV1UtMXYyVWJPeTR5WmloZE5VaWZvMHhETXBzNnVUS2Y?oc=5","date":"2024-11-14","type":"pipeline","source":"PR Newswire UK","summary":"Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - PR Newswire UK","headline":"Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxQek9qdmp2VWtSLVRlZlVBNjBKby1sT01mZ24xQU16clhZZUh2amlxeTNUUldaMXdoNWxEcEVBd2paZE1VUi1GVmx0S2xvWkQ3YmpwcmFoWDdyTEV5QUkzQ3dBbjd4WGpFQjYtcWZ3YlBhUTFvWGdVVlNmelJzLXZsRFBRaUswNUVaaktKOWJIQjBKbmRPV3lQYTdkclBxTnA1NjlFTGNLYjhwMHZkU3JibzVtZkI5WWFaaXNTc0hRc2pXM3U0OGJHTFl1UUoyb3dXb01XcXdGbk1DRlF5aW9sQmZMcmJrb0djX2ZCNW5BV0k?oc=5","date":"2024-10-17","type":"pipeline","source":"VisionMonday.com","summary":"Orasis Announces Licensing Agreement With Optus Pharmaceuticals for Commercialization of Qlosi Eye Drops in Korea - VisionMonday.com","headline":"Orasis Announces Licensing Agreement With Optus Pharmaceuticals for Commercialization of Qlosi Eye Drops in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxPQ0FMWnNFQUNDemg1cUNGaklOeVRHaDQwZmktMjhjVUxFOTlobko0UnBGRGc1ekZXdVhEbUwwT2xyRzF2M0N1R2I4SmV1TU9aNG8wbnlCMTNjU1ZmZWZBTUF6U2tzWVo4WTJmZ3d4MnlIV2ZENURzRDFMTnItam1QMlhCT010eWdqMlc0Z3dueWkyb3BvcEN5Z1NUanBIMzBxZFJDYWZMeWZlZV9Eay1FNjBPS3AtNGZTT25nQldoMEdQRk9hRnJlLWl6SEVxb3dKVERkTm1ualQ3dktnbHE4MUhuYXM5RlJaMXlUX2ZBYnZmSktlWXlSMldZUXZyT1NWdW1iaXRLQ3dwcFJIY0JteEVEQ3llVXR0dGJzUDM1cTJ1amVabGwzcHhCbGllZ190YkhWYk96ODRfb0Z1NEo0c3ZCVzVFYWZL?oc=5","date":"2024-10-16","type":"pipeline","source":"PR Newswire","summary":"Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea - PR Newswire","headline":"Orasis Pharmaceuticals Announces Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxPYndxeEpSbllWbjlreEhIUktXemdpZTctZy1lY3cxTGQyLTUzUlJ6bFJOemVVZ3dSYTZ0NFFpM1lHZzAtMFJqVjV0NWVDMFVDNnpKQmJjcGx2SEVhTHlnOVc4Tk5JMmxIWW5jRnNqaEphM29Wc1IzbnhIUWxvUlEtZk9Vb084aXpUd2hqdmd6cDA0cjRBakdpWkVQV21ZdE1TQWk3b3FXeEVIcGRMWVBiOS1Md3U0emNWUnZBZ2c5WlgtTnNsQUdvWWVkNnFnczVhUnBjWWxWdkp0NVBwS0JTaXl2VVpZc0pjNFNxU0h2UklkaEF6TUl3eXdCcXB5TFp6ck1IM2xsMVlUR3NmNWFNM3g4aGNNdnFDZng1bXBOVWFsNTJRbEgxVWtn?oc=5","date":"2024-10-14","type":"pipeline","source":"PR Newswire","summary":"Orasis Pharmaceuticals Strengthens Leadership Team with Key Hires to Support the Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% - PR Newswire","headline":"Orasis Pharmaceuticals Strengthens Leadership Team with Key Hires to Support the Launch of Qlosi™ (pilocarpine hydrochlo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQLXlGaHRtSVE4dWFmbE9lOTFOaWtSTDJnNWI3NXJLZ0IwUlhNT0wtMWNSTUVaZk82eldvLXZZbVQ5bGt2STZraGc3STZHUHFNYktqMUlweFR0Qi1nU3JsNEFodnVGTy1icjl0MUhEVkNIeThhQVJxZngtSE5NeHp5QU84d1FXcmxyMUd0NmRQU0lLMHF6TUtIWG9wZ29iY1hGRjlLLVNSb1FEa0YxSU13TEJxeDdVaFBXYk5JTjF1dllHSmQtZUtnZDBvcEpJMEdOM0JNT3pMTy03VkpIaDMxT0d1M0NpMzhvZ1E3M1ZYdC1xRlQ4UEwtZHRqMjlYdkpNZWMyd1Y4YlotRU1xTFgyYkE3a0M3alNWVDhMQm9YbFBRbHc?oc=5","date":"2024-10-08","type":"pipeline","source":"PR Newswire","summary":"Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% - PR Newswire","headline":"Orasis Pharmaceuticals Completes $78 Million Financing to Support Commercial Launch of Qlosi™ (pilocarpine hydrochloride","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPaldoSFBCU3JUci1oVjVGYklIRVUzOGd3ajExWUZIdFU0MEE0aUZjRnhsSVZJQVd6Tl91eXRGS1RnZWdaMmJycHhBTjUxZEM5MERPT3RWbGdxdy1uVHIzVGVKUlltSEU3YXRNZzRWdTk3dXIxdzQxZGRUSXAzWjhqMWR6OVFPS1NwM0R0eVpYX1Z2TV9zaUxUZm16enNYWDhzaW1CVlF6RlhLUU1xRlFMQXdaUlVrcWJVbzBQbjA3bi03bHRPMHJyclNCVGFWX05GdXdIOS1Gejd1TjhTZ1dMMDFvZnRxM0kybHBsdFdwTDNqSFlJbFl1bVkya0Y3ZlI0VDFWcl8xdENRMnc5TW5QaGVGOGwyRktZSnRLM2cwYw?oc=5","date":"2019-10-10","type":"pipeline","source":"GlobeNewswire","summary":"Orasis Pharmaceuticals Announces CSF-1 Eye Drop - GlobeNewswire","headline":"Orasis Pharmaceuticals Announces CSF-1 Eye Drop","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}